This slide from the AGM suggests that the "pothole" in the process was 100% in the process of the CDMO
Which begs the question where is the compensation and why were we not insured for such incidents?
Hard to believe its a "sorry about that chief" matter considering it has cost the company several $M in unconverted options
This is also notable considering if the hiccup didn't occur they were meant to be in-human trials now one must question how prepared they actually were considering this statement
These guys are rookies when you compare to some other bios who are run by proven drug developers and if PAB succeed it will more a case of good luck than good management.
Ann: Chair's Address and CEO Presentation to 2023 AGM, page-13
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $11.87K | 1.695M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 7388960 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2976726 | 5 |
View Market Depth
| Last trade - 10.06am 16/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |